Ran Nussbaum - Net Worth and Insider Trading
Ran Nussbaum Net Worth
The estimated net worth of Ran Nussbaum is at least $235 Million dollars as of 2024-06-10. Ran Nussbaum is the Director, 10% Owner of Keros Therapeutics Inc and owns about 4,794,507 shares of Keros Therapeutics Inc (KROS) stock worth over $233 Million. Ran Nussbaum is the Director of Kite Pharma Inc and owns about 5,611 shares of Kite Pharma Inc (KITE) stock worth over $1 Million. Ran Nussbaum is also the Director of Arqule Inc and owns about 8,611 shares of Arqule Inc (ARQL) stock worth over $172,220. Besides these, Ran Nussbaum also holds Eloxx Pharmaceuticals Inc (ELOX) . Details can be seen in Ran Nussbaum's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ran Nussbaum has not made any transactions after 2020-11-17 and currently still holds the listed stock(s).
Transaction Summary of Ran Nussbaum
Ran Nussbaum Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ran Nussbaum owns 8 companies in total, including Prevail Therapeutics Inc (PRVL) , UroGen Pharma Ltd (URGN) , and Eloxx Pharmaceuticals Inc (ELOX) among others .
Click here to see the complete history of Ran Nussbaum’s form 4 insider trades.
Insider Ownership Summary of Ran Nussbaum
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| PRVL | Prevail Therapeutics Inc | 2020-06-17 | director |
| URGN | UroGen Pharma Ltd | 2019-01-01 | director |
| ELOX | Eloxx Pharmaceuticals Inc | 2021-05-13 | director |
 | | 2020-11-17 | director & 10 percent owner |
| | 2020-01-16 | director |
| | 2017-10-30 | director |
| | 2017-10-03 | director |
| | 2013-01-25 | 10 percent owner |
Ran Nussbaum Latest Holdings Summary
Ran Nussbaum currently owns a total of 4 stocks. Among these stocks, Ran Nussbaum owns 4,794,507 shares of Keros Therapeutics Inc (KROS) as of November 17, 2020, with a value of $233 Million and a weighting of 99.46%. Ran Nussbaum owns 5,611 shares of Kite Pharma Inc (KITE) as of May 9, 2017, with a value of $1 Million and a weighting of 0.43%. Ran Nussbaum also owns 8,611 shares of Arqule Inc (ARQL) as of June 27, 2019, with a value of $172,220 and a weighting of 0.07%. The other 1 stocks Eloxx Pharmaceuticals Inc (ELOX) have a combined weighting of 0.04% among all his current holdings.
Latest Holdings of Ran Nussbaum
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KROS | Keros Therapeutics Inc | 2020-11-17 | 4,794,507 | 48.69 | 233,444,546 |
| KITE | Kite Pharma Inc | 2017-05-09 | 5,611 | 179.79 | 1,008,802 |
| ARQL | Arqule Inc | 2019-06-27 | 8,611 | 20.00 | 172,220 |
| ELOX | Eloxx Pharmaceuticals Inc | 2019-06-24 | 122,506 | 0.69 | 83,986 |
Holding Weightings of Ran Nussbaum
Ran Nussbaum Form 4 Trading Tracker
According to the SEC Form 4 filings, Ran Nussbaum has made a total of 2 transactions in Keros Therapeutics Inc (KROS) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Keros Therapeutics Inc is the acquisition of 60,000 shares on November 17, 2020, which cost Ran Nussbaum around $3 Million.
According to the SEC Form 4 filings, Ran Nussbaum has made a total of 0 transactions in Kite Pharma Inc (KITE) over the past 5 years. The most-recent trade in Kite Pharma Inc is the acquisition of 9,832 shares on May 9, 2017, which cost Ran Nussbaum around $679,490.
According to the SEC Form 4 filings, Ran Nussbaum has made a total of 1 transactions in Arqule Inc (ARQL) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Arqule Inc is the acquisition of 307,692 shares on June 27, 2019, which cost Ran Nussbaum around $3 Million.
More details on Ran Nussbaum's insider transactions can be found in the Insider Trading History of Ran Nussbaum table.Insider Trading History of Ran Nussbaum
- 1
Ran Nussbaum Trading Performance
GuruFocus tracks the stock performance after each of Ran Nussbaum's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ran Nussbaum is 21.2%. GuruFocus also compares Ran Nussbaum's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ran Nussbaum within 3 months outperforms 5 times out of 9 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ran Nussbaum's insider trading performs compared to the benchmark.
Performance of Ran Nussbaum
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 18.74 | | | | | |
| Relative Return to S&P 500(%) | 16.43 | | | | | |
Ran Nussbaum Ownership Network
Ran Nussbaum Owned Company Details
What does Prevail Therapeutics Inc do?
Who are the key executives at Prevail Therapeutics Inc?
Ran Nussbaum is the director of Prevail Therapeutics Inc. Other key executives at Prevail Therapeutics Inc include director & 10 percent owner Carl L Gordon , director & 10 percent owner Peter A. Thompson , and General Counsel Kira M. Schwartz .
Prevail Therapeutics Inc (PRVL) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Prevail Therapeutics Inc (PRVL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Prevail Therapeutics Inc (PRVL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Prevail Therapeutics Inc (PRVL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Prevail Therapeutics Inc Insider Transactions
Ran Nussbaum Mailing Address
Above is the net worth, insider trading, and ownership report for Ran Nussbaum. You might contact Ran Nussbaum via mailing address: C/o Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica Ca 90404.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
